Translate
Outlook Therapeutics Inc
About
Outlook Therapeutics Inc (NASDAQ:OTLK) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 23 2026
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
Apr 22 2026
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Apr 21 2026
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Apr 7 2026
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
Mar 25 2026
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Recent Videos
22 abril 26. Noticias acciones biotecnológicas. Resumen diario. #Español #Shorts #diario $XBI #bio
Apr 22, 2026
20 abril 26. Noticias acciones biotecnológicas. Resumen diario. #Español #Shorts #diario $XBI #bio
Apr 21, 2026
Outlook Therapeutics, Inc. (0001649989) (Filer) #Shorts
Apr 10, 2026
My Take on Outlook's FDA Dispute & Lytenava's Future
Apr 10, 2026
Financials
Revenue
$205.7 K
Market Cap
$20.99 M
EPS
-2.89